Research Article
Employing Adalimumab in Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Real-Life Multicenter Data from the Czech Republic
Table 1
Demographic and clinical patients’ characteristics.
| | | N (percentage)/Mean (±SD) |
| | Number of patients | 299 (100.0%) | | Men | 166 (55.5%) | | Age (years) | 44.9 (±12.9) | | Age at the time of diagnosis (years) | 33.6 (±13.1) | | Age at the time of initiation of adalimumab (years) | 42.7 (±12.7) | | Duration from diagnosis to the initiation of adalimumab (years) | 9.1 (±9.1) | | Previous surgery of HS | 186 (62.2%) | | Family history of HS | 51 (17.1%) | | Smokers + Ex-smokers | 237 (79.3%) | | Number of average cigarettes smoked per day | 13.8 (±8.5) | | Current job status—work absences | 11 (3.7%) | | Current job status—disability pension | 67 (22.4%) | | Comorbidities | 176 (58.9%) | | Arterial hypertension | 79 (26.4%) | | Diabetes mellitus type II | 41 (13.7%) | | Dyslipidemia | 27 (9.0%) | | Depression | 16 (5.4%) | | Anxiety disorder | 8 (2.7%) | | Crohn’s disease | 6 (2.0%) | | Ulcerative colitis | 1 (0.3%) | | Baseline BMI (kg/m2) | 30.8 (±5.9) | | Normal | 56 (18.7%) | | Overweight | 79 (26.4%) | | Obese | 164 (54.8%) | | Prior systemic antibiotic use | 282 (94.3%) | | Prior systemic retinoids use | 75 (25.1%) | | Prior autogenous vaccine therapy | 21 (7.0%) | | Prior systemic corticosteroid use | 7 (2.3%) | | Localization of disease | — | | Axillae | 220 (73.6%) | | Inframammary folds + breasts | 55 (18.4%) | | Genitofemoral area | 252 (84.3%) | | Gluteal area | 170 (56.9%) |
|
|
HS, hidradenitis suppurativa; BMI, body mass index.
|
